STATUS OF CLAIMS

1. (Amended) A composition able to treat acute pancreatitis in a mammal comprising,
   a. a first element comprising a binding element selected from the group consisting of i) a first peptide comprising an amino acid sequence consisting of SEQ ID NO. 2 or a contiguous fragment thereof containing at least the 8 C-terminal residues of such region, wherein the C-terminal phenylalanine is amidated and/or the aspartic acid residue 7 amino acids from the C-terminus thereof is sulfated, and ii) said first peptide wherein said phenylalanine and aspartic acid residue have not been modified, and wherein said binding element is able to specifically bind a CCK-A or CCK-B receptor under physiological conditions,
   b. a second element comprising a translocation element derived from a Clostridial neurotoxin able to facilitate the transfer of a polypeptide across a vesicular membrane in a pancreatic cell, and
   c. a third element, linked to and comprised in a separate polypeptide chain from said first and second elements, comprising a therapeutic element derived from a Clostridial neurotoxin able, when present in the cytoplasm of a pancreatic cell, to inhibit or block enzymatic secretion by said pancreatic cell, and wherein following binding of said first element to a pancreatic acinar cell said third element is transported across a pancreatic cell membrane.

2. (Currently amended) The composition of claim 1 wherein said pancreatic cell is an acinar cell [and said cell surface marker is a CCK receptor].

3. (Original) The composition of claim 1 wherein said therapeutic element will cleave a SNARE protein and cleavage of said SNARE protein inhibits said secretion.

4. (Original) The composition of claim 3 wherein said SNARE protein is selected from the group consisting of syntaxin, SNAP-25 and VAMP.

5. (Original) The composition of claim 2 wherein said therapeutic element will cleave a SNARE protein, wherein cleavage of said SNARE protein inhibits said secretion.

6. (Original) The composition of claim 5 wherein said SNARE protein is selected from the group consisting of syntaxin, SNAP-25 and VAMP.

7. (Currently amended) The composition of claim 5 wherein said [CCK receptor is] binding element binds the human CCK A receptor.

8. (Original) The composition of claim 5 wherein said binding element comprises an amino acid sequence consisting of SEQ ID NO: 6.

9. (Original) The composition of claim 8 wherein said binding element comprises an amino acid sequence consisting of SEQ ID NO: 5.

10. (Original) The composition of claim 9 wherein said binding element comprises an amino acid sequence consisting of SEQ ID NO: 4.

11. (Original) The composition of claim 10 wherein said binding element comprises an amino acid sequence consisting of SEQ ID NO: 3.

12. (Original) The composition of claim 11 wherein said binding element comprises an amino acid sequence consisting of SEQ ID NO:2.

13. (Original) The composition of claim 1 wherein said composition further comprises a spacer moiety separating said binding element from said translocation element.

14. (Original) The composition of claim 13 wherein said spacer moiety comprises a moiety selected from the group consisting of a hydrocarbon, a polypeptide other than an immunoglobulin hinge region, and a proline-containing polypeptide identical or analogous to an immunoglobulin hinge region.

15. (Original) The composition of claim 14 wherein said spacer moiety comprises a proline-containing polypeptide identical or analogous to an immunoglobulin hinge region.

16. (Original) The composition of claim 15 wherein said polypeptide comprises an amino acid sequence consisting of SEQ ID NO:11.

17. (Original) The composition of claim 7 wherein said composition further comprises a spacer moiety separating said binding element from said translocation element.

18. (Original) The composition of claim 17 wherein said spacer moiety comprises a moiety selected from the group consisting of a hydrocarbon, a polypeptide other than an immunoglobulin hinge region, and a proline-containing polypeptide identical or analogous to an immunoglobulin hinge region.

19. (Original) The composition of claim 18 wherein said spacer moiety comprises a proline-containing polypeptide identical or analogous to an immunoglobulin hinge region.

20. (Original) The composition of claim 19 wherein said polypeptide comprises an amino acid sequence consisting of SEQ ID NO:11.

21. (Original) The composition of claim 8 wherein said composition further comprises a spacer moiety separating said binding element from said translocation element.

22. (Original) The composition of claim 17 wherein said spacer moiety comprises a moiety selected from the group consisting of a hydrocarbon, a polypeptide other than an immunoglobulin hinge region, and a proline-containing polypeptide identical or analogous to an immunoglobulin hinge region.

23. (Original) The composition of claim 18 wherein said spacer moiety comprises a proline-containing polypeptide identical or analogous to an immunoglobulin hinge region.

24. (Original) The composition of claim 19 wherein said polypeptide comprises an amino acid sequence consisting of SEQ ID NO:11.

25-50 (Cancelled)